Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women?
Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women?作者机构：Department of Clinical Medicine and Surgery Section of Infectious Diseases University of Naples Federico II
出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)
年 卷 期：2016年第8卷第12期
页 面：557-565页
学科分类：1002[医学-临床医学] 100211[医学-妇产科学] 10[医学]
主 题：Hepatitis C virus infection Breastfeeding woman Antiviral therapy Pregnancy category Directacting antivirals
摘 要：Hepatitis C virus(HCV) affects about 3% of the world spopulation, with the highest prevalence in individuals under 40. The prevalence in pregnant women varies with geographical distribution(highest in developing countries). Prevalence also increases in sub-populations of women at high risk for blood-transmitted infections. HCV infection in pregnancy represents a non-negligible problem. However, most of the past antiviral regimens cannot be routinely offered to pregnant or breastfeeding women because of their side effects. We briefly reviewed the issue of treatment of HCV infection in pregnant/breastfeeding women focusing on the effects of the new direct-acting antivirals on fertility, pregnancy and lactation in animal studies and on the potential risk for humans based on the pharmacokinetic properties of each drug. Currently, all new therapy regimens are contraindicated in this setting because of lack of sufficient safety information and adequate measures of contraception are still routinely recommended for female patients of childbearing potential.
维普期刊数据库